NCT00299689View on ClinicalTrials.gov

Phase II Trial of Ontak With Metastatic Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions
Malignant Melanoma
Interventions
DRUG

Denileukin diftitox

12 mcg/kg IV (in vein) over 30 minutes on days 1 through 4 of each 21 day cycle for 4 cycles.

Trial Locations (1)

40202

James Graham Brown Cancer Center, Univ. of Louisville, Louisville

All Listed Sponsors
collaborator

University of Louisville

OTHER

lead

James Graham Brown Cancer Center

OTHER

NCT00299689 - Phase II Trial of Ontak With Metastatic Melanoma | Biotech Hunter | Biotech Hunter